Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Chester Koerner who wrote (16225)	3/2/1998 4:14:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

hey Chester, One problem that I have with Panretin is that the disease it's suppose to help, KS, has a very small target population. The disease is basically non existent in healthy adults and has mostly been the target of those who have the onset of AIDS. And therefore Panretin is not a block buster drug. What an NDA approval does do is allow LGND to step up a notch in the biopharm world as one that actaully has a drug approved by the FDA. If panretin can get off label use, that could help the company with their bottom line. But, once panretin is approved, we'll have to see how well it sells and whether or not doctors will prescribe it for other uses. Who knows, maybe panretin will make a good acne cream? Look what acne medicine did for MDRX.